Literature DB >> 30154391

YKL-40, Soluble IL-2 Receptor, Angiotensin Converting Enzyme and C-Reactive Protein: Comparison of Markers of Sarcoidosis Activity.

Pelin Uysal1, Sinem Durmus2, Volkan Sozer3, Remise Gelisgen4, Ekrem Cengiz Seyhan5, Fusun Erdenen6, Gonul Simsek7, Hafize Uzun8.   

Abstract

The aims of this study were to describe the clinical, radiological and immunological features of a population of sarcoidosis patients and to analyse chitinase-3-like protein 1 (YKL-40), soluble interleukin-2 receptor (sIL-2R), neopterin concentrations and adenosine deaminase (ADA) activity in serum of these patients in order to understand their potential as disease markers. Fifty-nine patients affected by chronic sarcoidosis, in active (20 patients) and inactive (39 patients) phase according to the clinical, radiological and laboratory criteria were studied. Serum YKL-40, sIL-2R, high-sensitive C-reactive protein (hs-CRP), neopterin levels and ADA activities were evaluated and compared with those of 25 healthy controls. Individuals with chronic sarcoidosis were significantly higher serum YKL-40, sIL-2R, neopterin, hs-CRP concentrations, angiotensin converting enzyme (ACE) and ADA activity than those of control subjects. Sarcoidosis patients in the active phase of the disease were significantly higher YKL-40, sIL-2R, hs-CRP levels and ACE activity than those in the inactive phase, while ADA activities and neopterin levels did not display any significant difference between the active and inactive disease groups. In comparison to the other parameters, as panel measurement of the serum YKL-40, sIL-2R, ACE and hs-CRP indicate a greater discrimination between active and inactive disease. The results indicate that serum YKL-40, sIL-2R, ACE and hs-CRP concentrations may be useful marker for monitoring sarcoidosis disease activity.

Entities:  

Keywords:  adenosine deaminase (ADA); angiotensin converting enzyme (ACE); chitinase-3-like protein 1 (YKL-40); high-sensitive C-reactive protein (hs-CRP); neopterin (NEO); sarcoidosis; soluble interleukin-2 receptor (sIL-2R)

Mesh:

Substances:

Year:  2018        PMID: 30154391      PMCID: PMC6164141          DOI: 10.3390/biom8030084

Source DB:  PubMed          Journal:  Biomolecules        ISSN: 2218-273X


  38 in total

1.  Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis.

Authors:  M W Ziegenhagen; M E Rothe; M Schlaak; J Müller-Quernheim
Journal:  Eur Respir J       Date:  2003-03       Impact factor: 16.671

2.  Association of serum amyloid A and oxidative stress with paraoxonase 1 in sarcoidosis patients.

Authors:  Jasmina Ivanišević; Jelena Kotur-Stevuljević; Aleksandra Stefanović; Slavica Spasić; Violeta Vučinić Mihailović; Jelica Videnović Ivanov; Zorana Jelić-Ivanović
Journal:  Eur J Clin Invest       Date:  2016-03-17       Impact factor: 4.686

3.  Impaired Vascular Function in Sarcoidosis Patients.

Authors:  I Tuleta; D Skowasch; L Biener; C Pizarro; R Schueler; G Nickenig; N Schahab; C Schaefer; S Pingel
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 4.  Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?

Authors:  Jens Kastrup
Journal:  Immunobiology       Date:  2011-04-30       Impact factor: 3.144

5.  Serum Angiotensin-Converting Enzyme Has a High Negative Predictive Value in the Investigation for Systemic Sarcoidosis.

Authors:  Rachael L Niederer; Ahmed Al-Janabi; Sue L Lightman; Oren Tomkins-Netzer
Journal:  Am J Ophthalmol       Date:  2018-07-24       Impact factor: 5.258

Review 6.  Pulmonary sarcoidosis.

Authors:  J P Lynch; E A Kazerooni; S E Gay
Journal:  Clin Chest Med       Date:  1997-12       Impact factor: 2.878

7.  Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis.

Authors:  Snjezana Rothkrantz-Kos; Marja P van Dieijen-Visser; Paul G H Mulder; Marjolein Drent
Journal:  Clin Chem       Date:  2003-09       Impact factor: 8.327

8.  Angiotensin-converting Enzyme as a Predictor of Extrathoracic Involvement of Sarcoidosis.

Authors:  Zehra Yasar; Mehmet Akif Özgül; Erdoğan Cetinkaya; Aysel Kargi; Şule Gül; Fahrettin Talay; Elif Tanriverdi; H Erhan Dincer
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2016-01-18       Impact factor: 0.670

9.  18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.

Authors:  Ruth G Keijsers; Fred J Verzijlbergen; Wim J Oyen; Jules M van den Bosch; Henk J Ruven; Heleen van Velzen-Blad; Jan C Grutters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-04       Impact factor: 9.236

10.  Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis.

Authors:  Enken Gundlach; Michael Marcus Hoffmann; Antje Prasse; Sonja Heinzelmann; Thomas Ness
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

View more
  8 in total

1.  Role of Neuron-Specific Enolase in the Diagnosis and Disease Monitoring of Sarcoidosis.

Authors:  Noriaki Sunaga; Yasuhiko Koga; Yoshimasa Hachisu; Koichi Yamaguchi; Masaki Aikawa; Norimitsu Kasahara; Yosuke Miura; Hiroaki Tsurumaki; Masakiyo Yatomi; Reiko Sakurai; Toshitaka Maeno; Takeshi Hisada
Journal:  Can Respir J       Date:  2022-05-26       Impact factor: 2.130

2.  Serum soluble interleukin-2 receptor level is a predictive marker for EBUS-TBNA-based diagnosis of sarcoidosis.

Authors:  Jun Miyata; Takunori Ogawa; Yoichi Tagami; Takashi Sato; Mikie Nagayama; Toshiyuki Hirano; Naofumi Kameyama; Koichi Fukunaga; Akihiko Kawana; Takashi Inoue
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-03-15       Impact factor: 0.670

3.  Diagnostic Value of Serum Chitinase-3-Like Protein 1 for Liver Fibrosis: A Meta-analysis.

Authors:  Xiaoting Huang; Jialing Zhuang; Yongqiang Yang; Jiaxin Jian; Wen Ai; Chunyong Liu; Wenzhi Tang; Changyu Jiang; Yongshen He; Lesheng Huang; Se Peng
Journal:  Biomed Res Int       Date:  2022-03-20       Impact factor: 3.411

4.  Pharmacological Inhibition of Chitotriosidase (CHIT1) as a Novel Therapeutic Approach for Sarcoidosis.

Authors:  Barbara Dymek; Piotr Sklepkiewicz; Michal Mlacki; Nazan Cemre Güner; Patrycja Nejman-Gryz; Katarzyna Drzewicka; Natalia Przysucha; Aleksandra Rymaszewska; Magdalena Paplinska-Goryca; Agnieszka Zagozdzon; Małgorzata Proboszcz; Łukasz Krzemiński; Jan H von der Thüsen; Katarzyna Górska; Karolina Dzwonek; Zbigniew Zasłona; Pawel Dobrzanski; Rafał Krenke
Journal:  J Inflamm Res       Date:  2022-09-29

Review 5.  Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects.

Authors:  Raisa Kraaijvanger; Montse Janssen Bonás; Adriane D M Vorselaars; Marcel Veltkamp
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

6.  Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis.

Authors:  Laura E M Eurelings; Jelle R Miedema; Virgil A S H Dalm; Paul L A van Daele; P Martin van Hagen; Jan A M van Laar; Willem A Dik
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

7.  Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis.

Authors:  David Bennett; Paolo Cameli; Nicola Lanzarone; Loredana Carobene; Nicola Bianchi; Annalisa Fui; Luigi Rizzi; Laura Bergantini; Giuseppe Cillis; Miriana d'Alessandro; Maria Antonietta Mazzei; Rosa Metella Refini; Piersante Sestini; Elena Bargagli; Paola Rottoli
Journal:  Respir Res       Date:  2020-01-06

8.  Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases.

Authors:  Laura Bergantini; Miriana d'Alessandro; Lucia Vietri; Giuseppe Domenico Rana; Paolo Cameli; Silvia Acerra; Piersante Sestini; Elena Bargagli
Journal:  Immunol Res       Date:  2020-10-22       Impact factor: 2.829

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.